Exagen Reports Record Revenue, Secures $65M Debt Facility & $22M Equity, Faces Widening Losses

summarizeSummary

Exagen Inc. reported record 2025 revenue of $66.6 million, a 19.7% increase, but net loss widened to $20.0 million. The company secured significant financing in 2025, including $18.6 million from a public offering and $3.4 million from an ATM program, alongside a $65.0 million debt facility, which led to substantial shareholder dilution.

check_boxKey Events

• Record Revenue Growth

  Exagen Inc. reported record full-year 2025 revenue of $66.6 million, marking a 19.7% increase from $55.6 million in 2024, driven by higher testing volume and average selling price.

• Widening Net Loss

  Despite revenue growth, the company's net loss increased to $20.0 million in 2025 from $15.1 million in 2024, contributing to an accumulated deficit of $314.3 million.

• Substantial Capital Raises

  In 2025, Exagen completed a public offering on May 9, 2025, raising $18.6 million net by issuing 3,852,500 shares at $5.25 per share, finalizing terms of an offering initiated under a November 2023 shelf registration. The company also sold $3.4 million net from an existing At-The-Market (ATM) program established on September 15, 2022, and secured a $65.0 million senior secured delayed draw term loan facility.

• Debt Facility Amendment

  A March 6, 2026 amendment to the Perceptive Term Loan Facility adjusted terms, including extending Tranche B availability to September 30, 2026, and revising financial covenants, while reducing future warrant vesting from 750,000 to 600,000 shares.

auto_awesomeAnalysis

This 10-K provides a comprehensive update on Exagen Inc.'s financial and operational status, highlighting both progress and ongoing challenges. The company achieved record revenue growth in 2025, indicating successful execution of its operational turnaround strategy and market adoption of its diagnostic tests. However, this growth was accompanied by a widening net loss and continued reliance on external financing. The public offering in May 2025 finalized the pricing and terms of a capital raise initiated under a November 2023 shelf registration, resulting in substantial shareholder dilution. Additional capital was raised through an existing ATM program and a large debt facility. The recent amendment to the debt facility and the reduction in potential warrant dilution are notable subsequent events. The dismissal of a significant qui tam lawsuit and the vacatur of the FDA's LDT rule are positive developments that reduce legal and regulatory overhangs. Investors should weigh the positive operational momentum and reduced legal/regulatory risks against the increasing losses and the significant capital raises, which have resulted in substantial shareholder dilution. The company's ability to achieve profitability and manage its debt and future capital needs will be critical.